J Bacteriol Virol.  2018 Sep;48(3):109-112. 10.4167/jbv.2018.48.3.109.

Omadacycline, a Magic Antibiotics for Bacterial Infections

• Rahman MS
• Koh YS

• KMID: 2421306
• DOI: http://doi.org/10.4167/jbv.2018.48.3.109

Abstract

Nowadays antibiotic resistance is a worldwide serious problem that mainly affects public health. Omadacycline is a unique antibiotic which has two available dosage forms such as intravenous (IV) and oral that development for community-acquired bacterial infectious disease treatment. It is a modified form of older tetracycline at C-9 aminomethyl substituent of 6-member core ring of tetracycline. Modification form shows its activity against efflux pump and ribosomal protein protection mechanism of tetracycline resistance. Generally, omadacycline is effective against methicillin-resistant S. aureus (MRSA), Streptococcus pneumoniae, vancomycin-resistant Enterococcus (VRE), Legionella and Chlamydia spp. Efficacy, safety and tolerability profile of omadacycline those compares with recent antibiotics shows that omadacycline is less resistant than others. One derivative from tetracycline derivatives is 9-neopentylaminomethylminocycline called omadacycline was discovered and ongoing phase III clinical experiments as a therapy for acute bacterial skin and skin structure infections (ABSSSI) as well as community-acquired bacterial pneumonia (CABP). Omadacycline seems to be a strong drug candidate for future promising new antibacterial agent that is effective against ABSSSI and CABP.

Keyword

Antibiotics; Omadacycline; Aminomethylcycline

MeSH Terms

Anti-Bacterial Agents*
Bacterial Infections*
Chlamydia
Communicable Diseases
Dosage Forms
Drug Resistance, Microbial
Enterococcus
Legionella
Magic*
Methicillin Resistance
Pneumonia, Bacterial
Public Health
Ribosomal Proteins
Skin
Streptococcus pneumoniae
Tetracycline
Tetracycline Resistance
Anti-Bacterial Agents
Dosage Forms
Ribosomal Proteins
Tetracycline

Reference

1). Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016; 24:6409–19.

2). Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, et al. Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline. Antimicrob Agents Chemother. 2015; 59:7044–53.

3). Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001; 65:232–60.

4). Draper MP, Weir S, Macone A, Donatelli J, Trieber CA, Tanaka SK, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014; 58:1279–83.

5). Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014; 58:1127–35.

6). Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012; 56:5650–4.

7). Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996; 40:2226–8.

8). Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, et al. Targetand resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012; 56:2559–64.

9). Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, et al. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent. J Med Chem. 2012; 55:597–605.

10). Zakeri B, Wright GD. Chemical biology of tetracycline antibiotics. Biochem Cell Biol. 2008; 86:124–36.

11). Connell SR, Tracz DM, Nierhaus KM, Taylor DE. Ribosomal Protection Proteins and Their Mechanism of Tetracycline Resistance. Antimicrob Agents Chemother. 2003; 47:3675–81.